In this study, statistical analysis revealed a significant difference in the occurrence of CDKN2A/B deletion between the two groups in terms of immunophenotype (P < 0.001), with a greater proportion of T-ALL patients in the CDKN2A/B deletion group than in the non-deletion group. This evidence concerns the gene CDKN2A and acute lymphoblastic leukemia.